DelveInsight’s “Aneurysmal Subarachnoid Hemorrhage Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Aneurysmal Subarachnoid Hemorrhage, historical and forecasted epidemiology as well as the Aneurysmal Subarachnoid Hemorrhage market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Aneurysmal Subarachnoid Hemorrhage market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Aneurysmal Subarachnoid Hemorrhage Market Forecast
Some of the key facts of the Aneurysmal Subarachnoid Hemorrhage Market Report:
-
The Aneurysmal Subarachnoid Hemorrhage market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
-
In May 2023, Acasti Pharma disclosed the submission of the GTX-104’s comprehensive protocol for its crucial Phase III safety investigation to the FDA. Concurrently, the company has initiated a strategic realignment initiative aimed at optimizing shareholder value.
-
In October 2022, Aspen Healthcare has recently forged an exclusive licensing deal with Brain Implant Therapeutics (BIT) Pharma for a Nicardipine-based intracerebral implant designed to mitigate vasospasm, a postoperative complication often observed in patients undergoing subarachnoid hemorrhage surgery.
-
In 2023, the United States accounted for the second-largest share of incident cases of aSAH among the 7 major markets, comprising approximately 24.5% of the total share.
-
According to DelveInsight’s analysis, the total number of incident cases of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the 7 major markets (7MM) was approximately 54,600 cases in 2023.
-
In 2023, Japan recorded the highest incident population of Aneurysmal Subarachnoid Hemorrhage (aSAH), with approximately 32,000 cases.
-
According to a study by Ziu et al. (2023), the annual incidence of subarachnoid hemorrhage in the United States ranges from 10 to 14 cases per 100,000 individuals.
-
Key Aneurysmal Subarachnoid Hemorrhage Companies: Acasti Pharma Inc., BIT Pharma, Aaron Cook, Haaglanden Medical Centre, and others
-
Key Aneurysmal Subarachnoid Hemorrhage Therapies: GTX-104, NicaPlant (nicardipine), Telavancin Injection, C1 Esterase Inhibitor Injection, and others
-
Subarachnoid hemorrhage (aSAH) is more prevalent in females, constituting approximately 66% of the total incident cases of aSAH.
-
The Aneurysmal Subarachnoid Hemorrhage market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Aneurysmal Subarachnoid Hemorrhage pipeline products will significantly revolutionize the Aneurysmal Subarachnoid Hemorrhage market dynamics.
Aneurysmal Subarachnoid Hemorrhage Overview
Aneurysmal Subarachnoid Hemorrhage (aSAH) is a type of stroke caused by bleeding into the space surrounding the brain, known as the subarachnoid space, due to the rupture of a brain aneurysm. This condition is characterized by sudden and severe headaches, often described as the worst headache of a person’s life, along with other symptoms such as nausea, vomiting, stiff neck, sensitivity to light, and loss of consciousness.
Get a Free sample for the Aneurysmal Subarachnoid Hemorrhage Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/aneurysmal-subarachnoid-hemorrhage-sah-market
Aneurysmal Subarachnoid Hemorrhage Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Aneurysmal Subarachnoid Hemorrhage Epidemiology Segmentation:
The Aneurysmal Subarachnoid Hemorrhage market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
-
Total Prevalence of Aneurysmal Subarachnoid Hemorrhage
-
Prevalent Cases of Aneurysmal Subarachnoid Hemorrhage by severity
-
Gender-specific Prevalence of Aneurysmal Subarachnoid Hemorrhage
-
Diagnosed Cases of Episodic and Chronic Aneurysmal Subarachnoid Hemorrhage
Download the report to understand which factors are driving Aneurysmal Subarachnoid Hemorrhage epidemiology trends @ Aneurysmal Subarachnoid Hemorrhage Epidemiology Forecast
Aneurysmal Subarachnoid Hemorrhage Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Aneurysmal Subarachnoid Hemorrhage market or expected to get launched during the study period. The analysis covers Aneurysmal Subarachnoid Hemorrhage market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Aneurysmal Subarachnoid Hemorrhage Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Aneurysmal Subarachnoid Hemorrhage Therapies and Key Companies
-
GTX-104: Acasti Pharma Inc.
-
NicaPlant (nicardipine): BIT Pharma
-
Telavancin Injection: Aaron Cook
-
C1 Esterase Inhibitor Injection: Haaglanden Medical Centre
Discover more about therapies set to grab major Aneurysmal Subarachnoid Hemorrhage market share @ Aneurysmal Subarachnoid Hemorrhage Treatment Landscape
Aneurysmal Subarachnoid Hemorrhage Market Strengths
-
Several trials are underway that may offer results that will further enhance the practice of the anesthesiologist and thus improve the short-term and long-term outcomes for aSAH
-
The 20th century has seen a great advancement in diagnosis, starting with ability to recognize the condition at all during life.
Aneurysmal Subarachnoid Hemorrhage Market Opportunities
-
Limited therapies are available for treatment aSAH; thus providing profitable opportunities for emerging therapies.
-
Demands of advanced therapeutics and the presence of a significant number of pipeline drugs.
-
High R&D investment and marketing outlay for innovative drugs.
Scope of the Aneurysmal Subarachnoid Hemorrhage Market Report
-
Study Period: 2019–2032
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Aneurysmal Subarachnoid Hemorrhage Companies: Acasti Pharma Inc., BIT Pharma, Aaron Cook, Haaglanden Medical Centre, and others
-
Key Aneurysmal Subarachnoid Hemorrhage Therapies: GTX-104, NicaPlant (nicardipine), Telavancin Injection, C1 Esterase Inhibitor Injection, and others
-
Aneurysmal Subarachnoid Hemorrhage Therapeutic Assessment: Aneurysmal Subarachnoid Hemorrhage current marketed and Aneurysmal Subarachnoid Hemorrhage emerging therapies
-
Aneurysmal Subarachnoid Hemorrhage Market Dynamics: Aneurysmal Subarachnoid Hemorrhage market drivers and Aneurysmal Subarachnoid Hemorrhage market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Aneurysmal Subarachnoid Hemorrhage Unmet Needs, KOL’s views, Analyst’s views, Aneurysmal Subarachnoid Hemorrhage Market Access and Reimbursement
To know more about Aneurysmal Subarachnoid Hemorrhage companies working in the treatment market, visit @ Aneurysmal Subarachnoid Hemorrhage Clinical Trials and Therapeutic Assessment
Table of Contents
1. Aneurysmal Subarachnoid Hemorrhage Market Report Introduction
2. Executive Summary for Aneurysmal Subarachnoid Hemorrhage
3. SWOT analysis of Aneurysmal Subarachnoid Hemorrhage
4. Aneurysmal Subarachnoid Hemorrhage Patient Share (%) Overview at a Glance
5. Aneurysmal Subarachnoid Hemorrhage Market Overview at a Glance
6. Aneurysmal Subarachnoid Hemorrhage Disease Background and Overview
7. Aneurysmal Subarachnoid Hemorrhage Epidemiology and Patient Population
8. Country-Specific Patient Population of Aneurysmal Subarachnoid Hemorrhage
9. Aneurysmal Subarachnoid Hemorrhage Current Treatment and Medical Practices
10. Aneurysmal Subarachnoid Hemorrhage Unmet Needs
11. Aneurysmal Subarachnoid Hemorrhage Emerging Therapies
12. Aneurysmal Subarachnoid Hemorrhage Market Outlook
13. Country-Wise Aneurysmal Subarachnoid Hemorrhage Market Analysis (2019–2032)
14. Aneurysmal Subarachnoid Hemorrhage Market Access and Reimbursement of Therapies
15. Aneurysmal Subarachnoid Hemorrhage Market Drivers
16. Aneurysmal Subarachnoid Hemorrhage Market Barriers
17. Aneurysmal Subarachnoid Hemorrhage Appendix
18. Aneurysmal Subarachnoid Hemorrhage Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/